Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio , a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease.
Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020. Full results are available here. MRT5500 is being developed under a collaboration agreement between Sanofi Pasteur and Translate Bio.
2026-10-17
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Which Protein Is Present In Covid 19
-
Which Is The Best Covid Vaccine In The World
-
Interpretation Of Omicron Covid Variant Symptoms
-
A Look At The Worst Hit Covid Countries
-
Nitric Oxide Nasal Spray Prevents Spread of Coronavirus, Clinical Trials Show
-
'Delta MayJust Be A Warning', New Variant Of COVID-19 May Emerge
-
What Other Vaccines Use mRNA And The Application Of Homogeneous Technology In mRNA Vaccine And Drug Development.
-
Does Vaccine Protect Against Omicron? Zhang Wenhong : Vaccination Booster Is Still An Effective Tool To Deal With Omicron
-
Shanghai Company's Self-Developed COVID-19 mRNA Vaccine Approved For Clinical Trials And mRNA Vaccines Animal Trials
-
mRNA Vaccine Production Process : LNP Delivery Technology
Recommend Reading
-
AkzoNobel Invests €50 Million to Expand Aerospace Coatings Operations in the United States
-
Sinopec and LG Chem Sign Agreement to Jointly Develop Sodium-Ion Battery Materials
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Two Major Chemical Companies Collapse in May as the Global Industry Faces a Broad Downturn
-
AstraZeneca and CSPC Strengthen Biologics Manufacturing Partnership in China
-
Cost Side Stops Falling and Rebounds; PC Prices Stabilize and Consolidate in November
-
Applications of Caesium Iodide
-
Rumors of Production Resumption Break Lithium Carbonate's Upside Trend
-
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
-
Rally and Retreat! Epichlorohydrin Falls Back to 10,000 Yuan per Ton